Trial reportMedical oncology (Northwood, London, England)2025
Prospective study comparing acute toxicity and objective response rate between simultaneous integrated boost and sequential boost Intensity-Modulated radiation therapy for locally advanced head and neck squamous cell carcinoma.
Trial report in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) were included for evaluation of patient characteristics, dosimetric analysis, and plan evaluation of both intensity-modulated radiotherapy (RT) using simultaneous integrated boost (SIB-IMRT) and sequential IMRT (IMRTSEQ) and to compare the response and acute toxicity of both arms. This prospective single-blind randomized clinical comparative study was carried out on 60 patients, clinically and histologically confirmed to have locally advanced HNSCC at the Clinical Oncology Department, Tanta University Hospitals. All patients were randomly divided into two equal groups: Group A was treated with SEQ-IMRT with combined total doses in phases I, II, and III of 70 Gy/35 fractions, 2 Gy/fraction along the entire course, 5 days a week, in 7 weeks by 54 Gy in 27 fractions, and group B was treated with SIB-IMRT dose of 66 Gy to PTV-HR (2.2 Gy/fraction), 60 Gy to PTV-IR (2 Gy/fraction), and 54 Gy to PTV-LR (1.8 Gy/fraction), all were given at the same time in 30 fractions, 5 days a week, over 6 weeks. All patients received 3 cycles of induction chemotherapy with docetaxel (or Taxotere), platinum, and 5-fluorouracil, followed by concurrent chemo-RT with cisplatin or carboplatin. Organ at risk )OAR( was higher for group B (100%) vs. (33.3%) for group A (p = 0.035). The 1-year & 2-year OS for the whole group were (98.3% & 61.5%) respectively, while for group A and group B, 1-year OS was 96.7% for group A vs. 100.0% for group B, and the 2-year OS was 53.2% for group A vs. 71.2% for group B. the 2-year PFS was 58.3% for the whole group and 49.4% vs. 69.2% for groups A and B, respectively. The SIB-IMRT arm, with shorter total treatment duration, resulted in comparable treatment outcomes and acute toxicity rates. This reduction in treatment time not only reduces costs but also decreases the workload of busy radiation. The SIB-IMRT is well-tolerated with better treatment compliance for head and neck cancer patients.
Indexed as
Identifiers
41240223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.